A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy. Researchers analyzed peripheral ...

Patients with some types of lymphoma that become resistant to standard treatments may benefit from a therapy that University of Wisconsin–Madison researchers are evaluating after they discovered a key ...

Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings ...

MIAMI, FLORIDA (EMBARGOED UNTIL FEB. 1, 2024, AT 2 P.M. ET) – New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating ...

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer Patients accrued to four sequential studies of ibrutinib were included in these analyses. Deep sequencing for BTK ...

New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations has identified a next-generation BTK degrader that could ...